| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24588SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77668SS | |||
| Azide and BSA Free | NBP2-80903 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1327SS | |||
| Azide and BSA Free | NBP2-80626 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-25164SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-25959SS | |||
| Azide and BSA Free | NBP2-80902 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19167SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-985-0.025mg | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | NBP1-26550 | |||
![Immunohistochemistry-Paraffin: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 Antibody [NBP2-24588]. Human pancreas probed with RIPK3/RIP3 antibody at 10 ug/ml.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Immunohistochemistry-Paraffin-NBP2-24588-img0004.jpg "Immunohistochemistry-Paraffin: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 Antibody [NBP2-24588]. Human pancreas probed with RIPK3/RIP3 antibody at 10 ug/ml.")
![<b>Biological Strategies Validation. </b>Western Blot: RIPK3/RIP3 Antibody [NBP2-24588] - Representative western blot analysis of RIP1, RIPK3/RIP3, and beta-actin in WI-38 NCs and IR-SCs 24 h after incubation with Veh or 10 uM PL. A cell lysate of etoposide-treated Jurkat cells was used as a positive control. Image collected and cropped by CiteAb from the following publication (//www.aging-us.com/article/101100/text) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP2-24588-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: RIPK3/RIP3 Antibody [NBP2-24588] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with RIPK3/RIP3 Antibody [NBP2-24588] at a 1:200 dilution overnight at 4C and detected with DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin was used at a 1:1000 dilution as a co-stain and detected with DyLight 550 (Red) at a 1:500 dilution. Nuclei were detected with DAPI (Blue) at 2.0ug/ml in 1X PBS. Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-24588-img0003.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 antibody [NBP2-24588]. Human tissue blot probed with 5 ug/ml of RIP3 antibody: 1) brain, 2) heart, 3) small intestine, 4) kidney, 5) liver, 6) lung, 7) skeletal muscle, 8) stomach, 9) spleen, 10) ovary, 11) testis, 12) placenta probed at 5 ug/ml, 13) Ramos cell lysate probed at 7 ug/ml. Theoretical molecular weight 56.7 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP2-24588-img0005.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP2-24588] - HOIP limits the activity of TRAIL‐induced apoptosis‐ & necroptosis‐mediating signalling complexesControl & HOIP KO HeLa cells were treated with FLAG‐lz‐TRAIL (500 ng/ml) for the indicated times. The TRAIL complex I was immunoprecipitated via anti‐FLAG beads. Complex II was isolated by immunoprecipitating caspase‐8 from complex I‐depleted lysates. Western blot was performed using the indicated antibodies. * indicates unspecific bands.WT & HOIP‐deficient TNF KO MEFs, pre‐treated for 1 h with zVAD, were stimulated with iz‐TRAIL (1 μg/ml) for the indicated times. FADD‐containing complexes were immunoprecipitated & analysed by Western blot.Data information: See also Fig EV2. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28258062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24588_rabbit-polyclonal-ripk3-rip3-antibody-31020241534394.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP2-24588] - The catalytic activity of HOIP contributes to preventing TRAIL‐induced apoptosis but is dispensable for preventing necroptosisLysates from control or HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S analysed by WB.HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre‐treated w/ zVAD and/or Nec‐1s for 1 h as indicated, treated w/ iz‐TRAIL (1 μg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 5; mean ± SEM). *P < 0.05, **P < 0.01; statistics performed using ANOVA.Control & HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S treated w/ iz‐TRAIL (100 ng/ml) for the indicated times. Lysates analysed w/ the indicated antibodies.Lysates from TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S analysed by WB.TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre‐treated w/ zVAD & Nec‐1s for 1 h as indicated, treated w/ iz‐TRAIL (1 μg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 4; mean ± SEM). *P < 0.05, ***P < 0.001; statistics performed using ANOVA.TNF KO HOIP KO MEFs reconstituted w/ empty vector, pre‐treated w/ zVAD and/or the RIPK3 inhibitor GSK'872 for 1 h as indicated, treated w/ iz‐TRAIL (1 μg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 3; mean ± SEM). *P < 0.05; statistics performed using t‐test.TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre‐treated w/ zVAD for 1 h, treated w/ iz‐TRAIL (1 μg/ml) for the indicated times. FADD‐containing complexes immunoprecipitated & analysed by WB. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28258062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24588_rabbit-polyclonal-ripk3-rip3-antibody-310202416114733.jpg)
![Immunohistochemistry-Paraffin: COX-2 Antibody [NB100-689] - Formalin fixed paraffin embedded colon carcinoma stained with COX-2 antibody (NB100-689).](http://images.novusbio.com/fullsize/COX-2-Antibody-Immunohistochemistry-Paraffin-NB100-689-img0010.jpg "Immunohistochemistry-Paraffin: COX-2 Antibody [NB100-689] - Formalin fixed paraffin embedded colon carcinoma stained with COX-2 antibody (NB100-689).")
![Simple Western: COX-2 Antibody [NB100-689] - Simple Western lane view shows a specific band for COX2 in 1.0 mg/ml of Rat Brain at an antibody concentration of 1:100. This experiment was performed under reducing conditions using the 12-230 kDa separation system. Image provided through customer review.](http://images.novusbio.com/fullsize/COX-2-Antibody-Simple-Western-NB100-689-img0003.jpg)
![Western Blot: Panendothelial Cell Antigen Antibody (MECA-32) [NB100-77668] - Total protein from human Colon, Thyroid and Stomach was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-Panendothelial Cell Antigen (NB100-77668) in blocking buffer and detected with an anti-rat HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/Panendothelial-Cell-Antigen-Antibody-MECA-32-Western-Blot-NB100-77668-img0009.jpg "Western Blot: Panendothelial Cell Antigen Antibody (MECA-32) [NB100-77668] - Total protein from human Colon, Thyroid and Stomach was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-Panendothelial Cell Antigen (NB100-77668) in blocking buffer and detected with an anti-rat HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).")
![Immunohistochemistry-Paraffin: Panendothelial Cell Antigen Antibody (MECA-32) [NB100-77668] - Panendothelial Cell Antigen (MECA-32) was detected in immersion fixed paraffin-embedded sections of human spleen. Antibody at 1:500 for 1 hour at room temperature followed by incubation with the Anti-Rat IgG VisUCyte(TM) HRP Polymer Antibody (Catalog # VC005). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the endothelial cells.](http://images.novusbio.com/fullsize/Panendothelial-Cell-Antigen-Antibody-MECA-32-Immunohistochemistry-Paraffin-NB100-77668-img0008.jpg)
![Flow Cytometry: Panendothelial Cell Antigen Antibody (MECA-32) [NB100-77668] - Analysis using the PerCP conjugate of NB100-77668. Staining of bEND.3 cells with MECA-32 AF488.](http://images.novusbio.com/fullsize/Panendothelial-Cell-Antigen-Antibody-MECA-32-Flow-Cytometry-NB100-77668-img0007.jpg)
![Western Blot: Panendothelial Cell Antigen Antibody (MECA-32) [NB100-77668] - Mouse embryonic cell lysate (A). Antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/Panendothelial-Cell-Antigen-Antibody-MECA-32-Western-Blot-NB100-77668-img0006.jpg)
![Western Blot: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds](http://images.novusbio.com/fullsize/USP7-Antibody-Western-Blot-NB100-513-img0004.jpg "Western Blot: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds")
![Immunohistochemistry-Paraffin: USP7 Antibody [NB100-513] - Sample: FFPE section of human ovarian carcinoma.Antibody: Affinity purified rabbit anti-USP7 used at 1:5,000 (0.2ug/ml). Detection:DAB](http://images.novusbio.com/fullsize/USP7-Antibody-Immunohistochemistry-Paraffin-NB100-513-img0002.jpg)
![Immunohistochemistry-Paraffin: USP7 Antibody [NB100-513] - Sample: FFPE section of mouse renal cell carcinoma.Antibody: Affinity purified rabbit anti-USP7 used at 1:5,000 (0.2ug/ml). Detection:DAB](http://images.novusbio.com/fullsize/USP7-Antibody-Immunohistochemistry-Paraffin-NB100-513-img0001.jpg)
![Immunoprecipitation: USP7 Antibody [NB100-513] - Samples: Wholecell lysate (10 ug) from HEK293T, RKO, Hep-G2, Jurkat,HeLa, TCMK-1, and NIH 3T3 cells prepared using NETNlysis buffer. Antibody: Affinity purified rabbit anti-USP7antibody used for WB at0.04 ug/ml. Detection: Chemiluminescence with anexposure time of 10 seconds](http://images.novusbio.com/fullsize/USP7-Antibody-Immunoprecipitation-NB100-513-img0003.jpg)
![Immunohistochemistry: CD11b Antibody (M1/70.15) [NB600-1327] - Immunohistochemical analysis of frozen lymph node section using CD11b Antibody (M1/70.15) [NB600-1327] followed by staining with HRP-conjugated secondary antibody.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunohistochemistry-NB600-1327-img0012.jpg "Immunohistochemistry: CD11b Antibody (M1/70.15) [NB600-1327] - Immunohistochemical analysis of frozen lymph node section using CD11b Antibody (M1/70.15) [NB600-1327] followed by staining with HRP-conjugated secondary antibody.")
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Characterization of microglia cultures by multiple staining with CD11b Antibody (M1/70.15) [NB600-1327] (panels a. & c.) and anti GFAP (panels b & d). Nuclei appear blue due to 4',6-diamidino-2-phenylindole (DAPI) counter staining.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0013.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - A surface stain was performed on Raw264.7 cells with CD11b (M1/70.15) Antibody [NB600-1327R] (blue) and a matched isotype control (orange), both conjugated to DyLight 550. Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) - BSA Free [NB600-1327] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody [M1/70.15] (NB600-1327) at 1ug/ml overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1327-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) - BSA Free [NB600-1327] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody [M1/70.15] conjugated to Alexa Fluor 488 (NB600-1327AF488) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1327-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Immunocytochemistry/Immunofluorescence (ICC/IF) analysis of RAW264.7 cells using CD11b antibody (M1/70.15) [NB600-1327] with Dylight 488 conjugated secondary (green). Nuclei and tubulin were stained with 4',6-diamidino-2-phenylindole (DAPI) (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Immunocytochemical/Immunofluorescent staining in untreated and treated mouse microglia cells using CD11b Antibody (M1/70.15) [NB600-1327]. Image from a verified customer review.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0015.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) [NB600-1327] - Immunocytochemical/Immunofluorescent analysis in mouse primary microglia. Cells were treated with lysophosphatidic acid (LPA) or LPA and an LPAR5 inhibitor in order to investigate the expression of iNOS after 24 hours. CD11b Antibody (M1/70.15) [NB600-1327] was used in a dilution 1:100 in order to stain primary murine microglia. Cy2 (green) and Cy3 (red) were used as secondary antibodies.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Immunocytochemistry-Immunofluorescence-NB600-1327-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: CD11b Antibody (M1/70.15) - BSA Free [NB600-1327] - Raw264.7 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD11b Antibody [M1/70.15] conjugated to Alexa Fluor 647 (NB600-1327AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1327-img0019.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - Staining of mouse peritoneal macrophages with Rat anti Mouse CD11b Antibody (M1/70.15) [NB600-1327].](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0004.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - Staining of mouse peritoneal macrophages with Rat anti Mouse CD11b Antibody (M1/70.15) [NB600-1327]: RPE - Alexa Fluor 750](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0007.jpg)
![Flow Cytometry: CD11b Antibody (M1/70.15) [NB600-1327] - Staining of mouse peritoneal macrophages using the Alexa Fluor (R) 488 conjugate of CD11b Antibody (M1/70.15) [NB600-1327AF488].](http://images.novusbio.com/fullsize/CD11b-Antibody-M1-70-15-Flow-Cytometry-NB600-1327-img0014.jpg)
![Immunocytochemistry/ Immunofluorescence: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - Validation of UBQLN2 antibody for staining of endogenous UBQLN2 in U2OS cells. U2OS cells were transfected with control siRNA or siRNA targeting UBQLN2. Cells were either seeded as separate groups (i.e., control and UBQLN2 siRNA) or mixed 1:1 and seeded together. Cells were stained using the mouse monoclonal anti-UBQLN2 6H9 (Novus NBP2-25164), at 1:250 in 2% BSA PBS for 1h. Secondary antibody was goat Anti-Mouse DyLight 488. Knockdown of UBQLN2 can be clearly seen to decrease the signal, indicating that the antibody is specific to UBQLN2. (G) displays zoom of the indicated areas in. For the mixed cells a white arrowhead indicates a cell transfected with control siRNA and a black arrowhead a cell transfected with UBQLN2 siRNA. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1016/j.cell.2016.07.001), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ubiquilin-2-Antibody-6H9-Knockdown-Validated-NBP2-25164-img0010.jpg "<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - Validation of UBQLN2 antibody for staining of endogenous UBQLN2 in U2OS cells. U2OS cells were transfected with control siRNA or siRNA targeting UBQLN2. Cells were either seeded as separate groups (i.e., control and UBQLN2 siRNA) or mixed 1:1 and seeded together. Cells were stained using the mouse monoclonal anti-UBQLN2 6H9 (Novus NBP2-25164), at 1:250 in 2% BSA PBS for 1h. Secondary antibody was goat Anti-Mouse DyLight 488. Knockdown of UBQLN2 can be clearly seen to decrease the signal, indicating that the antibody is specific to UBQLN2. (G) displays zoom of the indicated areas in. For the mixed cells a white arrowhead indicates a cell transfected with control siRNA and a black arrowhead a cell transfected with UBQLN2 siRNA. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1016/j.cell.2016.07.001), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Simple Western: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - Simple Western lane view shows a specific band for Ubiquilin 2 in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Ubiquilin-2-Antibody-6H9-Simple-Western-NBP2-25164-img0007.jpg)
![Western Blot: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - Analysis of different tissue and cell lysates using mouse mAb to ubiquilin 2, NBP2-25164, dilution 1:1,000 in green: [1] protein standard (red), [2] NIH-3T3, [3] C6, [4] HEK293, [5] HeLa, [6] SH-SY5Y, [7] rat whole brain, and [8] mouse whole brain. The band at 65-70kDa corresponds to ubiquilin 2 protein, which is known to differ between the human and rodent proteins.](http://images.novusbio.com/fullsize/Ubiquilin-2-Antibody-6H9-Western-Blot-NBP2-25164-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - Analysis of an NIH-3T3 cell culture stained with mouse mAb to ubiquilin 2, NBP2-25164, dilution 1:1,000 in green, and costained with chicken pAb to lamin A/C, dilution 1:5,000 in red. The blue is DAPI staining of nuclear DNA. The cells were treated with 50uM of chloroquine, an inhibitor of autophagy, for 16 hours prior to staining. NBP2-25164 antibody reveals vesicular staining of ubiquilin 2 protein accumulated in lysosomes in the cytoplasm, while the lamin A/C antibody stains the nuclear lamina.](http://images.novusbio.com/fullsize/Ubiquilin-2-Antibody-6H9-Immunocytochemistry-Immunofluorescence-NBP2-25164-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - Analysis of Human U2OS cells stained with Ubiquilin 2 antibody. Primary antibody dilution: 1:1000. Image from verified customer review.](http://images.novusbio.com/fullsize/Ubiquilin-2-Antibody-6H9-Immunocytochemistry-Immunofluorescence-NBP2-25164-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - HeLa cell cultures stained with NBP2-25164 (green) and chicken polyclonal antibody to Vimentin: NB300-223 (red). In most individual cells Ubiquilin 2 is present diffusely in the cytoplasm of cells, though some cells show enrichment of the protein in spherical autophagosome-like structure.](http://images.novusbio.com/fullsize/Ubiquilin-2-Antibody-6H9-Immunocytochemistry-Immunofluorescence-NBP2-25164-img0003.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - Lysates of HAP1 WT and Ubiquilin 2 KO were prepared, and 30 ug of protein were processed for immunoblot with NBP2-25164. The Ponceau stained transfer of the blot is shown. Antibody dilution used: 1/2000. Predicted band size: 65 kDa. Image, protocol and testing courtesy of YCharOS Inc. (ycharos.com).](http://images.novusbio.com/fullsize/Ubiquilin-2-Antibody-6H9-Knockout-Validated-NBP2-25164-img0012.jpg)
![Immunoprecipitation: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - HAP1 lysates were prepared, and immunoprecipitation was performed using 2.0 ug of Ubiquilin 2 antibody (NBP2-25164) pre-coupled to Dynabeads protein G. Samples were washed and processed for immunoblot with NBP2-25164. For immunoblot, Recombinant Ubiquilin 2 (Rb x Ubiquilin 2) was used at 1/1000. The Ponceau stained transfer of the blot is shown. SM=4% starting material; UB=4% unbound fraction. Image, protocol and testing courtesy of YCharOS Inc. (ycharos.com).](http://images.novusbio.com/fullsize/Ubiquilin-2-Antibody-6H9-Immunoprecipitation-NBP2-25164-img0013.jpg)
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: Ubiquilin 2 Antibody (6H9) [NBP2-25164] - HAP1 WT and Ubiquilin 2 KO cells were labeled with a green or a far-red fluorescent dye, respectively. WT and KO cells were mixed and plated to a 1:1 ratio in a 96-well plate with glass bottom. Cells were stained with Ubiquilin-2 antibody (NBP2-25164) and with the corresponding Alexa-fluor 555 coupled secondary antibody including DAPI. Acquisition of the blue (nucleus-DAPI), green (identification of WT cells), red (antibody staining) and far-red (identification of KO cells) channels was performed. Representative image of the blue and red (grayscale) channels is shown. WT and KO cells are outlined with green and magenta dashed line, respectively. Antibody dilution used: 1/1000. Bars = 10 um Image, protocol and testing courtesy of YCharOS Inc. (ycharos.com).](http://images.novusbio.com/fullsize/Ubiquilin-2-Antibody-6H9-Knockout-Validated-NBP2-25164-img0014.jpg)
![Immunocytochemistry/ Immunofluorescence: Palladin Antibody (1E6) [NBP1-25959] - C2C12 cells were transfected with shRNA targeting palladin or nontargeting shRNA as a control. Stable transfectants were submitted to a differentiation medium and followed for 5 days in culture (D0 to D5). Myogenic differentiation was assessed at the indicated time points using RNA/protein analysis and immunofluorescence staining. Immunofluorescence images of stable transfectants labeled with palladin antibody (green) and F-actin (red). Blue is DAPI-stained nuclei. Scale bar is 10 um. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0124762) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Palladin-Antibody-1E6-Knockdown-Validated-NBP1-25959-img0012.jpg "<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: Palladin Antibody (1E6) [NBP1-25959] - C2C12 cells were transfected with shRNA targeting palladin or nontargeting shRNA as a control. Stable transfectants were submitted to a differentiation medium and followed for 5 days in culture (D0 to D5). Myogenic differentiation was assessed at the indicated time points using RNA/protein analysis and immunofluorescence staining. Immunofluorescence images of stable transfectants labeled with palladin antibody (green) and F-actin (red). Blue is DAPI-stained nuclei. Scale bar is 10 um. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0124762) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Western Blot: Palladin Antibody (1E6) [NBP1-25959] - MDA-MB-231 lysate.](http://images.novusbio.com/fullsize/Palladin-Antibody-1E6-Western-Blot-NBP1-25959-img0003.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: Palladin Antibody (1E6) [NBP1-25959] - Western blots analysis of C2C12 cells labeled with a monoclonal antibody against 90-kDa palladin or a polyclonal antibody against 140- and 200-kDa palladin, MyHC, myogenin, and MLC. The blots clearly show the decrease in palladin expression concomitant with the elevation of differentiation markers. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0124762) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Palladin-Antibody-1E6-Knockdown-Validated-NBP1-25959-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: Palladin Antibody (1E6) [NBP1-25959] - Immunofluorescence on a7r5 cells.](http://images.novusbio.com/fullsize/Palladin-Antibody-1E6-Immunocytochemistry-Immunofluorescence-NBP1-25959-img0005.jpg)
![Western Blot: Palladin Antibody (1E6) [NBP1-25959] - Western blot analysis of HeLa (A), A431 (B), NIH3T3 (C), and PC-12 (D) cell line extracts using Palladin antibody at 1ug/ml.](http://images.novusbio.com/fullsize/Palladin-Antibody-1E6-Western-Blot-NBP1-25959-img0009.jpg)
![Immunohistochemistry-Paraffin: Palladin Antibody (1E6) [NBP1-25959] - Palladin was detected in immersion fixed paraffin-embedded sections of human heart using Mouse Anti-Human Palladin (1E6) Monoclonal Antibody (Catalog # NBP1-25959) at 1:100 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm in cardiomyocytes.](http://images.novusbio.com/fullsize/Palladin-Antibody-1E6-Immunohistochemistry-Paraffin-NBP1-25959-img0010.jpg)
![Flow Cytometry: Palladin Antibody (1E6) [NBP1-25959] - An intracellular stain was performed on HeLa cells with Palladin Antibody [1E6] NBP1-25959AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/Palladin-Antibody-1E6-Flow-Cytometry-NBP1-25959-img0011.jpg)
![Immunohistochemistry: Palladin Antibody (1E6) [NBP1-25959] - Palladin staining of paraffin-embedded patient tissues.A. IHC staining was performed using standard antigen-retrieval protocols, & counter-stained with hematoxylin. Tissue sections were stained for palladin using two palladin antibodies: polyclonal 622 & monoclonal 1E6. Palladin stain is detected with brown reaction product. In tumor sections, palladin is detected at dramatically elevated levels in the stromal fibroblasts. Note also the expanded stroma around the neoplastic cells, which is characteristic of the desmoplastic reaction. Scale bars, 200 µM. B. Quantification of immunohistochemistry results. Ten sections each of normal pancreatitis & adenocarcinoma specimens were stained with four different antibodies (622, COM, 1E6 & 4D10) & scored by two pathologists, as described in the text. Results for both ductal epithelium (left) & stroma (right) stained with various palladin antibodies are shown for normal pancreas (n = 9, blue), pancreatitis (n = 7, red) & pancreatic adenocarcinoma (n = 10, yellow). The results confirmed that palladin levels are increased in the stroma, & not the epithelial tumor cells, of the adenocarcinomas. Although palladin levels are also increased in cases of chronic pancreatitis, they do not reach the same levels as in the tumors. Compared to the polyclonal 622 & COM, the monoclonal antibodies 1E6 & 4D10 are effective at distinguishing between pancreatitis & cancer. C. Double-label immunostaining for palladin (1E6 Ab) & alpha -SMA in sections of pancreatic tumors confirms that palladin is strongly detected in a population of activated TAFs that surround the neoplastic cells. Scale bars, 200 µM. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0010347), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-25959_mouse-monoclonal-palladin-antibody-1e6-310202416173545.jpg)
![Western Blot: Palladin Antibody (1E6) [NBP1-25959] - Analysis of human palladin isoforms in pancreatic tissues.A. Human palladin isoforms. Proline-rich domains are represented by red boxes, & Ig-like domains are shown as blue boxes. The epitope recognized by the 1E6 & 4D10 antibodies is highlighted in green. The region amplified by RT-qPCR is highlighted in light blue. Isoform #1, 3 & 4 are the primary products of the palladin gene & have been detected by immunoblotting. The sequences of these isoforms are published. The sequences of isoforms #2, 5, 6, & 7 were obtained from genomic databases. “ND”: not-determined. B. Western blot analysis of pancreas samples. Small pieces of fresh tissue were snap-frozen in liquid nitrogen, ground in a chilled mortar & pestle, extracted in a detergent-containing lysis buffer, & centrifuged at 15,000×g to remove any unsolubilized particulates. The supernatant was boiled in Laemmli sample buffer & resolved by SDS-PAGE, with 15 µg protein loaded per lane. The samples were immunoblotted & probed with two anti-palladin antibodies & an antibody to GADPH (a housekeeping gene) as a control for equal loading. Lanes 1–2: normal pancreas. Lanes 3–5: primary adenocarcinoma tumors (PDA). Lane 6–7: Non-primary adenocarcinoma tumors (Non-PDA) (Lane 6: solid pseudopapillary tumor, Lane 7: neuroendocrine tumor). C. RT-qPCR. Total RNA was isolated from normal tissue (patients 1–4) & PDA tumors (patients 1–3), reverse transcribed, & subjected to RT-qPCR using gene-specific primers. Each bar represents the mean + SEM (0.06–0.35%) from three or more independent determinations. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0010347), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-25959_mouse-monoclonal-palladin-antibody-1e6-31020241616073.jpg)
![Western Blot: Palladin Antibody (1E6) [NBP1-25959] - Detection of palladin in post-surgical samples collected with 18-gauge needles.A. Samples of normal (lane 1 to 3) & pancreatic adenocarcinoma (lanes 4 to 7) were obtained from donated post-surgical organs using 18-gauge needles. Tissue samples were snap-frozen, ground, lysed & analyzed as in Figure 1. The blot was stained with both monoclonal (1E6) & polyclonal (622) palladin antibodies, & the major band (85–90 kDa) was detected by both antibodies in all tumor samples. B. Same samples (normal, lane 1–3 & PDA, lane 4–7) were analyzed for epithelial vs myofibroblast markers. The blot was stained with both, anti-E-cadherin antibody (as an epithelial cell marker) & anti-alpha SMA antibody (as a myofibroblast marker). Blots were stained for tubulin as a control for equal loading. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0010347), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-25959_mouse-monoclonal-palladin-antibody-1e6-310202416161829.jpg)
![Western Blot: Palladin Antibody (1E6) [NBP1-25959] - CAFs & NOFs are biochemically & morphologically different & CAF exosomes can also be transferred to CRC cells(A) Western blot of paired primary NOFs & CAFs for myofibroblastic markers alpha-smooth muscle actin ( alpha -SMA), fibronectin ED-A (ED-A FN1), palladin & vimentin. HSC-70 was used as an equal loading control. (B) Light microscopy of representative primary NOF & CAF cells (10x). (C) Fluorescence microscopy demonstrating phalloidin staining of F-actin filaments (green), counterstained with DAPI (blue; 40x). (D) Mean surface area & (E) intensity of phalloidin staining in a representative NOF-CAF pair. (F) Flow cytometry of DLD1 cells (control) & DLD1 cells co-cultured with CAF exosomes (exosome). The proportion of cells under the M1 region is given as a percentage. (G) Co-culture of CAF exosomes with DLD1 & SW480 cells with resultant increase in miR-199b & miR-21-5p. Data is presented as mean +/− SEM. Student's t-test (D, E) or paired t-test (F, G): *p<0.05, **p<0.01, ***p<0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29283887), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-25959_mouse-monoclonal-palladin-antibody-1e6-310202416173529.jpg)
![Immunocytochemistry/ Immunofluorescence: Palladin Antibody (1E6) [NBP1-25959] - Effect of palladin depletion on terminal differentiation of C2C12 cells.(A) Phase contrast images of stable transfectants at late stages of differentiation. Scale bar is 50 μm. (B) Representative immunofluorescence images of stable transfectants at day 5 of differentiation. Cells were labeled with palladin (red), MyHC (green), & DAPI (blue). Scale bar is 100 μm. (C) Fusion index analysis of stable transfectants at day 5 (left) & day 7 (right) of differentiation. A minimum of 4,000 nuclei were counted from random fields of each cell line. Note that palladin depletion resulted in a decrease of the fusion index at the late stage of differentiation. (D) Quantification of multinucleated myotubes throughout the course of differentiation. (E) Quantification of the number of MyHC-positive cells in stable transfectants. All error bars indicate the means ± SD of at least four independent experiments. * indicates statistically significant difference from control cells, * p<0.05, ** p<0.01, *** p<0.001 by Student’s t-test. ns = not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25875253), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-25959_mouse-monoclonal-palladin-antibody-1e6-310202416171480.jpg)
![Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.](http://images.novusbio.com/fullsize/LC3A-Antibody-Western-Blot-NBP1-19167-img0012.jpg "<b>Biological Strategies Validation. </b>Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: LC3A Antibody [NBP1-19167] - LC3/MAP1 [NBP1-19167] - LC3 antibody was tested in HeLa cells with Dylight 488 (green). Cells were treated overnight with 50 uM chloroquine to induce autophagosome formation. Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-19167-img0013.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse brain using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the cells with highest positivity in various neurons.](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0014.jpg)
![Western Blot: LC3/MAP1LC3A Antibody [NBP1-19167] - Human brain lysate.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Western-Blot-NBP1-19167-img0004.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse liver using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the hepatocytes and other liver cells.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0010.jpg)
![Simple Western: LC3A Antibody [NBP1-19167] - Image shows a specific band for LC3 in 0.5 mg/mL of Neuro2A lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Simple-Western-NBP1-19167-img0009.jpg)
![Western Blot: Mitofusin 1 Antibody (3C9) [H00055669-M04] - Analysis of MFN1 expression in HepG2.](http://images.novusbio.com/fullsize/Mitofusin-1-Antibody-3C9-Western-Blot-H00055669-M04-img0005.jpg "Western Blot: Mitofusin 1 Antibody (3C9) [H00055669-M04] - Analysis of MFN1 expression in HepG2.")
![Western Blot: Mitofusin 1 Antibody (3C9) [H00055669-M04] - MFN1 monoclonal antibody (M04), clone 3C9 Western Blot analysis of MFN1 expression in HeLa ( Cat # L013V1 ).](http://images.novusbio.com/fullsize/Mitofusin-1-Antibody-3C9-Western-Blot-H00055669-M04-img0001.jpg)
![Western Blot: Mitofusin 1 Antibody (3C9) [H00055669-M04] - Western blot analysis of MFN1 over-expressed 293 cell line, cotransfected with MFN1 Validated Chimera RNAi or non-transfected control. Blot probed with H00055669-M04. GAPDH (36.1 kDa) used as loading control.](http://images.novusbio.com/fullsize/Mitofusin-1-Antibody-3C9-Western-Blot-H00055669-M04-img0003.jpg)
![Western Blot: Mitofusin 1 Antibody (3C9) [H00055669-M04] - Analysis of MFN1 expression in transfected 293T cell line by MFN1 monoclonal antibody (M04), clone 3C9. Lane 1: MFN1 transfected lysatE (84.2 KDa). Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/Mitofusin-1-Antibody-3C9-Western-Blot-H00055669-M04-img0006.jpg)
![ELISA: Mitofusin 1 Antibody (3C9) [H00055669-M04] - Detection limit for recombinant GST tagged MFN1 is 0.3 ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/Mitofusin-1-Antibody-3C9-ELISA-H00055669-M04-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (ED1) [NB600-985] - Cynomolgus monkey spleen. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Immunohistochemistry-Paraffin-NB600-985-img0012.jpg "Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (ED1) [NB600-985] - Cynomolgus monkey spleen. IHC-P image submitted by a verified customer review.")
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat peritoneal macrophages cells.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0008.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat peritoneal macrophages.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0009.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat peritoneal macrophages](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0010.jpg)
![Immunohistochemistry-Frozen: CD68/SR-D1 Antibody (ED1) [NB600-985] - The feline macrophage containing section was incubated with the antibody at 1:50 and the section was further stained with Alexa secondary antibody. Image was captured with an epifluorescence microscope. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Immunohistochemistry-Frozen-NB600-985-img0015.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Decidual Macrophages were analyzed with a BD LSRFortessa. Antibody was diluted 1:100 in staining buffer before use. Isotype control is in Red. Sample with NB600-985AF700 is in Blue. Image from the Alexa Fluor 700 version of this antibody.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0016.jpg)
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat liver](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Immunohistochemistry-Paraffin-NB600-985-img0011.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - Staining of rat peritoneal macrophages cells.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0007.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (ED1) [NB600-985] - An intracellular stain was performed on Jurkat cells with BAK antibody (8B4) NBP1-74026PE (blue) and a matched isotype control NB600-985PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin. Image using the PE form of this antibody.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Cytometry-NB600-985-img0013.jpg)
![Flow (Intracellular): CD68/SR-D1 Antibody (ED1) [NB600-985] - An intracellular stain was performed on U-937 cells with CD68/SR-D1 Antibody (ED1) NB600-985PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-ED1-Flow-Intracellular-NB600-985-img0014.jpg)
![Immunohistochemistry-Frozen: Collagen IV Antibody [NBP1-26549] - Left panel: NBP1-26549 signal, identifying Collagen IV in extracellular basement membrane of brain endothelial cells. Right panel: counterstained image with DAPI. Mouse brain tissue (12um thickness) was incubated overnight with NBP1-26549 (1:400) in PBS 1x at 4C. The day after, the slide was washed 3 x PBS 1x and then incubated with secondary anti-goat antibody (Alex Fluor 568-conjugated), 1:1000 for 2 hours at r.t. After counterstaining with DAPI, image was acquired with confocal microscopy. Left panel: NBP1-26549 signal, identifying Collagen IV in extracellular basement membrane of brain endothelial cells. Right panel: counterstained image with DAPI. Image from verified customer review.](http://images.novusbio.com/fullsize/Collagen-IV-Antibody-Immunohistochemistry-Frozen-NBP1-26549-img0004.jpg "Immunohistochemistry-Frozen: Collagen IV Antibody [NBP1-26549] - Left panel: NBP1-26549 signal, identifying Collagen IV in extracellular basement membrane of brain endothelial cells. Right panel: counterstained image with DAPI. Mouse brain tissue (12um thickness) was incubated overnight with NBP1-26549 (1:400) in PBS 1x at 4C. The day after, the slide was washed 3 x PBS 1x and then incubated with secondary anti-goat antibody (Alex Fluor 568-conjugated), 1:1000 for 2 hours at r.t. After counterstaining with DAPI, image was acquired with confocal microscopy. Left panel: NBP1-26549 signal, identifying Collagen IV in extracellular basement membrane of brain endothelial cells. Right panel: counterstained image with DAPI. Image from verified customer review.")
![Immunohistochemistry-Paraffin: Collagen IV Antibody [NBP1-26549] - Human gastric cancer tissue was stained with Goat IgG-UNLB isotype control (left) and Goat Anti-Type IV Collagen-UNLB; (right) followed by Swine Anti-Goat IgG(H+L), Human/Rat/Mouse SP ads-HRP DAB, and hematoxylin.](http://images.novusbio.com/fullsize/Collagen-IV-alpha-1-Antibody-Immunohistochemistry-Paraffin-NBP1-26549-img0001.jpg)
![Immunohistochemistry: Collagen IV Antibody [NBP1-26549] - Col-IV in the rhesus macaque and baboon intramural tube. Images of open fallopian tube (m, o) were obtained from control animals. Occluded tube (n, p) were from animals treated with 5% PF. Arrows indicate fibrotic response. All images were captured at original magnification 200x. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27417518) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-IV-Antibody-Immunohistochemistry-NBP1-26549-img0002.jpg)
![Immunohistochemistry: Collagen IV Antibody [NBP1-26549] - Photographs showing Col-IV staining in rhesus macaque ampulla. Staining for Col-IV was undetectable from the epithelium. No increase in collagen was detected in the PF-treated animals. Control inset shows staining with an irrelevant antibody. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27417518) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Collagen-IV-Antibody-Immunohistochemistry-NBP1-26549-img0003.jpg)
![Immunohistochemistry: Collagen IV Antibody [NBP1-26549] - Photographs showing H&E staining & immunostaining for Col-I, Col-III, Col-IV & Col-V in the rhesus macaque & baboon intramural tube. Images of open fallopian tube (a, c, e, g, i, k, m, o, q & s) were obtained from control animals. Occluded tube (b, d, f, h, j, l, n, p, r & t) were from animals treated with 5% PF. Arrows indicate fibrotic response. All images were captured at original magnification ×200. Insets (frame r & s) show negative control with an irrelevant antibody. Treatment with PF increased collagen immunoreactivity in the lamina propria of the intramural tube. Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S0010782416301445), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-26549_goat-polyclonal-collagen-iv-antibody-310202415395955.jpg)
![Immunohistochemistry: Collagen IV Antibody [NBP1-26549] - Photographs showing H&E staining & immunostaining for Col-I, Col-III, Col-IV & Col-V in the rhesus macaque & baboon intramural tube. Images of open fallopian tube (a, c, e, g, i, k, m, o, q & s) were obtained from control animals. Occluded tube (b, d, f, h, j, l, n, p, r & t) were from animals treated with 5% PF. Arrows indicate fibrotic response. All images were captured at original magnification ×200. Insets (frame r & s) show negative control with an irrelevant antibody. Treatment with PF increased collagen immunoreactivity in the lamina propria of the intramural tube. Image collected & cropped by CiteAb from the following publication (//linkinghub.elsevier.com/retrieve/pii/S0010782416301445), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-26549_goat-polyclonal-collagen-iv-antibody-310202415334930.jpg)